Vanarix offers a new solution to treat cartilage lesions. Indeed, once damaged, cartilage has a very limited capacity for self-repair and, if left untreated, often evolves into osteoarthritis, the most common joint disorder.
Vanarix has developed and recently patented a method for the production of Cartibeads™, which are the first high-quality hyaline cartilage microtissues resembling native articular cartilage. This innovative product aims to regenerate cartilage damage and targets focal lesions and early osteoarthritis.
In 2024, the company reached many milestones:
- 4 millions CHF raised
- Phase I/IIa clinical trial with 10/10 patients recruited and transplanted with autologous Cartibeads to treat cartilage damage in the knee
- 2nd clinical trial with allogeneic Cartibeads underway
- 3 horse patients treated with allogeneic Cartibeads
